2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2933

Non-Invasive Tape Sampling Reveals RNA Gene Clusters in Cutaneous Lupus Erythematosus That Discriminate Affected from Unaffected and Healthy Volunteer Skin
Abstract Number: 220

Non-Medical Switch to Biosimilars: What Have We Learned?
Abstract Number: 1069

Non-Receptor Protein Tyrosine Phosphatase 14 (PTPN14) Promotes YAP-Dependent Tgfbeta Signaling in RA FLS
Abstract Number: 567

Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Abstract Number: 682

Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Abstract Number: 2601

Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
Abstract Number: 2982

Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Abstract Number: 2626

Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
Abstract Number: 2627

Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
Abstract Number: 2249

Not Just a Swollen Big Toe: Increasing All-Cause Hospitalizations in Patients with Gout in the United States: 1993–2014
Abstract Number: 43

Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Abstract Number: 2682

Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Abstract Number: 2296

Novel Classification of Idiopathic Inflammatory Myopathies Based on Distinctive Features and Autoantibodies: Analysis of 67 Korean Patients
Abstract Number: 2208

Novel Fluorescence Optical Imaging Scoring System of Inflammation in the Hand and Wrist Is in Patients with Rheumatoid Arthritis – Agreement with Ultrasonography and Sensitivity to Change
Abstract Number: 2020

Novel Serum Biomarkers Monitor Disease Progression and Response to Change in Corticosteroid Therapy in Children with Juvenile Dermatomyositis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].